Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Jun;58(6):339-45.
doi: 10.1038/jhg.2013.41. Epub 2013 May 23.

Pharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation?

Christina G Perry  1 , Alan R Shuldiner
Affiliations
Review

Pharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation?

Christina G Perry et al. J Hum Genet. 2013 Jun.

Abstract

Pharmacogenomics, the study of the genomics of drug response and adverse effects, holds great promise for more effective individualized (personalized) medicine. Recent evidence supports a role of loss-of-function (LOF) variants in the cytochrome P450 enzyme CYP2C19 as a determinant of clopidogrel response. Patients given clopidogrel after percutaneous coronary intervention who carry LOF variants do not metabolize clopidogrel, a prodrug, into its active form resulting in decreased inhibition of platelet function and a higher likelihood of recurrent cardiovascular events. Despite a large body of evidence supporting clinical utility, adoption of anti-platelet pharmacogenetics into clinical practice has been slow. In this review, we summarize the pharmacokinetic, pharmacodynamic and clinical evidence, identify gaps in knowledge and other barriers that appear to be slowing adoption, and describe CYP2C19 pharmacogenetics implementation projects currently underway. Only when we surmount these barriers will clinicians be able to use pharmacogenetic information in conjunction with the history, physical examination and other medical tests and information to choose the most efficacious anti-platelet therapy for each individual patient.

PubMed Disclaimer

Conflict of interest statement

Disclosures

Ms. Perry has no conflicts to disclose.

Figures

Figure 1
Figure 1
Summary of results from the Pharmacogenomics of Anti-platelet Intervention (PAPI) Study. Panel A. Distribution of ADP-stimulated platelet aggregation before (upper panel) and after (lower panel) 7-days of clopidogrel exposure in 420 PAPI Study participants. Panel B. Genome-wide association analysis of clopidogrel response in the PAPI Study (upper panel) revealing genome-wide significant associations in the region of the CYP2C18-CYP2C19-CYP2C9-CYP2C8 cluster on chromosome 10 (lower panel). Panel C. Association of the loss of function CYP2C19*2 variant (rs4244285) with ADP-stimulated platelet aggregation post-clopidogrel (lower panel) but not pre-clopidogrel (upper panel) in PAPI Study participants. Figure adapted from Shuldiner
See this image and copyright information in PMC

References

    1. Kushner FG, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2009;54:2205–41. - PubMed
    1. Anderson JL, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation. 2007;116:e148–304. - PubMed
    1. Mega JL, et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet. 2010;376:1312–9. - PMC - PubMed
    1. Fisch AS. Pharmacogenomics of Anti-platelet and Anti-coagulation Therapy. Current Cardiology Reports. In Press. - PMC - PubMed
    1. Ancrenaz V, et al. Impact of genetic polymorphisms and drug-drug interactions on clopidogrel and prasugrel response variability. Curr Drug Metab. 2010;11:667–77. - PubMed

Publication types

MeSH terms

LinkOut - more resources